This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Rocket Stocks to Buy in November

Abbott Laboratories

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Abbott Laboratories ( ABT) isn't what it once was. And that's a good thing for investors.

>>3 Stocks in Breakout Territory

Abbott split off its legacy pharmaceutical business from the rest of its efforts on Jan. 1, leaving pharma in the hands of AbbVie ( ABBV). The remaining "New Abbott" manufactures medical devices, nutritional products, diagnostic equipment and some generic drugs. While that business lacks the massive cash flows that pharmaceuticals provided, it also lacks the patent cliff discount that's been hoisted on the industry.

The medical business offers some attractive positioning in its own right. Powerhouse offerings such as Xience stents and high-margin nutritional brands generate plenty of free cash flow, and the firm is already much leaner after applying its spin-off proceeds to its debt load. That debt load, incidentally, has been reduced from $20 billion at the start of the year to a much more manageable $7.9 billion as of the most recent quarter. Going forward, more of that cash should be allocated to dividends; for now, ABT's payout weighs in at a 2.4% yield.

An aging baby boomer population in the U.S. should provide a big tailwind for Abbott in the years to come. Coupled with massive cost-savings efforts, ABT should generate significant multiplying power in its bottom line - at this point, too many one-time spinoff charges are still baked into the 2013 pie to give investors fair metrics.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ABT $37.13 0.00%
KR $38.33 0.00%
NKE $56.42 0.00%
PEP $98.49 0.00%
WY $22.60 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs